+1-888-308-5802     
News Contact Us

Glenmark & Harbour BioMed team up, develop cancer antibodies in China

Author : Saipriya Iyer | Published Date : 2018-08-08 

Mumbai-based Glenmark Pharmaceuticals has reportedly announced an exclusive license agreement with China-based Harbour BioMed. The deal, worth more than $120 million, showcases China’s willingness to transform healthcare by encouraging innovation.

Sources cite that the agreement aims at developing, producing & commercializing Glenmark’s GBR 1302 drug for the greater China region where the prevalence of certain HER2 positive cancer cases generates a clinical need.

A press release by Glenmark Pharma states that the GBR 1302 is a part of Glenmark’s patented BEAT platform and is a bispecific antibody that targets CD3 & HER2. It is utilized for the treatment of HER2 positive cancers. The drug is reportedly undergoing enrollment in the U.S. & Germany, and works by stimulating the immune system to fight against the HER2 overexpressing tumor cells.

The company would receive an upfront payment and payments on achieving certain development level, commercial & regulatory milestones, tiered royalties from Harbour BioMed on product sales.

Glenmark Chairman and MD, Glenn Saldanha expressed his delight about establishing this strategic relationship with Harbour BioMed whose extensive local experience will aid Glenmark in discovering, developing & innovating drugs for certain unfulfilled medical needs.

Harbour BioMed Founder & CEO, Dr. Jingsong Wang stated that this partnership aligns with their plan of leveraging company’s expertise in clinical development by in-licensing innovative clinical-stage products. He further added that the GBR 1302 compliments their internal portfolio of innovative antibody therapeutics.

Glenmark President and Chief Scientific Officer, Kurt Stoeckli stated that both companies follow the same principles and possess a common vision of developing highly effective & precise medicines to help cancer patients. He added that they look forward to achieving this goal together.

Post the announcement, Glenmark Pharma started trading 0.91% higher at about Rs. 602 per share, cite trusted sources.

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Ramping production of lithium-ion batteries to accelerate tert-amylbenzene demand in Asia Pacific

Published Date: 2021-01-05         Author: Saipriya Iyer

As an active pharmaceutical ingredient (API) used in various clinical products to being used as an electronic additive in the making of lithium-ion batteries, tert amylbenzene (TAB) has gained wide-spread recognition across diverse industries. The chemical substance acts as a crucial intermediate in... Read More

FMCG firms to explore oral care market amidst rising hygiene concerns

Published Date: 2021-01-04         Author: Saipriya Iyer

Fast-moving consumer goods businesses in India are reportedly expanding their range of oral care, joining new and niche categories including mouthwashes, ayurvedic mouth cleansers, and mouth sprays as customer issues around general hygiene persists. For the record, Dabur India and Colgate Palmoli... Read More

Microsoft to introduce ‘Google assistant’ alternative for Windows

Published Date: 2020-12-28         Author: Saipriya Iyer

Microsoft Corporation, an American multinational technology giant, is reportedly testing a new voice launcher feature which will enable users to interact with files and applications using voice commands. According to trusted sources, the feature is currently available to select group of users who... Read More

© 2021 Fractovia. All Rights Reserved